# US Neuropsychiatric Disorders Treatment Market > US Neuropsychiatric Disorders Treatment Market Research Report By Type (Degenerative Diseases, Neurotic Disorders, Psychosis, Others), By Application (Shock Treatment, Drug Treatment, Others) and By End User (Hospitals, Clinics, Research Centre’s, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.55% - **2024:** $ 32.99 Billion - **2025:** $ 36.14 Billion - **2035:** $ 90 Billion - **Key Players:** Johnson & Johnson (US), Pfizer Inc. (US), Eli Lilly and Company (US), AstraZeneca PLC (GB), Bristol-Myers Squibb Company (US), Novartis AG (CH), Roche Holding AG (CH), Sanofi S.A. (FR), AbbVie Inc. (US) **Report ID:** MRFR/HC/18441-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-neuropsychiatric-disorders-treatment-market-19988 --- ## Market Summary ## **US Neuropsychiatric Disorders Treatment Market Overview** As per MRFR analysis, the US Neuropsychiatric Disorders Treatment Market Size was estimated at 27.64 (USD Billion) in 2023. The US Neuropsychiatric Disorders Treatment Market Industry is expected to grow from 30.5(USD Billion) in 2024 to 88.7 (USD Billion) by 2035. The US Neuropsychiatric Disorders Treatment Market CAGR (growth rate) is expected to be around 10.191% during the forecast period (2025 - 2035) ## **Key US Neuropsychiatric Disorders Treatment Market Trends Highlighted** The US Neuropsychiatric Disorders Treatment Market is undergoing significant movement because of factors such as the increasing awareness of mental health and the growing population of people suffering from neuropsychiatric disorders. According to the National Institute of Mental Health, millions of people in America are suffering from issues related to mental health, which creates a need for effective treatment options. Especially during the COVID-19 pandemic, telemedicine became increasingly popular, enabling patients to receive mental healthcare through online consultations from home. This change not only reduces treatment barriers but also meets contemporary needs in terms of how healthcare is provided. There is room for the creation of new therapies, particularly in the fields of personalized medicine and digital therapeutics. With advancements in technology, incorporating mobile health applications and even wearable health devices into treatment regimens provides patients with more ways to manage their diseases. Furthermore, there does appear to be a growing willingness towards alternative therapies that utilize traditional medicine, such as holistic mindfulness and wellness programs. Most recently, there has been an observable increase in focus on collaborative care, where psychiatrists focus on working with primary care providers in order to optimize treatment. It is possible to see improvement in the funding and resources allocated for neuropsychiatric due to the new legislative support and better control of mental healthcare treatment. Additionally, as the stigma around mental health issues continues to reduce, more and more people are talking and showing interest in different forms of treatment. The US Neuropsychiatric Disorders Treatment Market is set to improve overall because of the new trends and opportunities emerging in the market that intend to offer better treatment for people suffering from neuropsychiatric disorders. ## **US Neuropsychiatric Disorders Treatment Market Drivers** ### **Increasing Prevalence of Neuropsychiatric Disorders** The rising incidence of neuropsychiatric disorders in the United States is a significant driver for the US Neuropsychiatric Disorders Treatment Market Industry. According to the National Institute of Mental Health (NIMH), nearly one in five adults in the US experience mental illness each year. This equates to approximately 51.5 million individuals who require treatment each year. The growing awareness and understanding of mental health issues have led to greater demand for neuropsychiatric treatments. Furthermore, the Centers for Disease Control and Prevention (CDC) reports that depression rates have increased by approximately 18% from 2005 to 2015, highlighting an urgent need for effective treatment options. As the population ages, the prevalence of conditions such as dementia is also expected to rise, further propelling the demand for neuropsychiatric treatments to manage these disorders effectively. ### **Advancements in Treatment Technologies** Innovations in treatment technologies, such as the development of novel pharmacotherapies and neuromodulation techniques, are key drivers for growth in the US Neuropsychiatric Disorders Treatment Market Industry. The introduction of advanced therapies, including deep brain stimulation and transcranial magnetic stimulation, is contributing to improved outcomes for patients with treatment-resistant conditions. The Food and Drug Administration (FDA) has approved multiple new drugs that offer alternatives to traditional treatments, which broadens the therapeutic landscape.As these advancements continue, they are expected to meet the needs of an increasing patient population, ultimately fostering growth in this market. ### **Government Initiatives and Funding** Government initiatives aimed at mental health awareness and funding create favorable conditions for the growth of the US Neuropsychiatric Disorders Treatment Market Industry. Programs such as the National Mental Health Act and the Mental Health Parity and Addiction Equity Act of 2008 aim to ensure that mental health services are accessible and adequately funded. National and state-level efforts promote the integration of mental health services into primary healthcare, which is crucial for early detection and treatment. According to the National Institute of Mental Health (NIMH), federal spending on mental health services has grown, helping to alleviate the financial burden of care on patients and families. This increased funding not only enhances treatment availability but also contributes to ongoing research and development, leading to improved therapies and outcomes. ## **US Neuropsychiatric Disorders Treatment Market Segment Insights** ### **Neuropsychiatric Disorders Treatment Market Type Insights** The US Neuropsychiatric Disorders Treatment Market has clearly delineated segments that cater to various types of disorders, underscoring the market's complexity and the tailored approach required for effective treatment. Among these, degenerative diseases represent a significant category, including ailments like Alzheimer's and Parkinson's disease, which primarily affect cognitive function and motor skills. The aging population in the United States plays a pivotal role in the growth of this segment, as it is characterized by higher incidences of these disorders. Neurotic disorders, encompassing anxiety and mood-related issues, are prevalent and reflect the rising stress levels in contemporary society, making them a crucial aspect of neuropsychiatric care. This segment illustrates the need for innovative therapeutic solutions as patients seek relief from symptoms that profoundly impact their daily lives. Moreover, psychosis, including schizophrenia and severe mood disturbances, holds a critical place in the market due to the complexity of treatment required and the societal implications of these conditions. The US has seen increased attention toward early intervention and comprehensive treatment plans for such disorders, highlighting their impact on both individuals and communities. Additionally, the category of "others" encompasses various miscellaneous disorders, reflecting the vast spectrum of neuropsychiatric conditions. These lesser-known disorders are often underrepresented yet require substantial resources to manage and treat effectively. Overall, the diversity within these segments illustrates the multifaceted nature of the US Neuropsychiatric Disorders Treatment Market, where different areas necessitate distinct approaches for diagnosis and management, paving the way for a more focused and efficient healthcare model that aligns with patient needs. Market growth in this domain is supported by ongoing research, the development of advanced treatment methodologies, and an increasing acknowledgment of mental health issues, all of which indicate a forward momentum in addressing neuropsychiatric disorders across the United States. ### **Neuropsychiatric Disorders Treatment Market Application Insights** The US Neuropsychiatric Disorders Treatment Market encompasses a diverse range of applications, notably including Shock Treatment, Drug Treatment, and others that contribute to addressing various neuropsychiatric conditions. Drug Treatment remains a crucial element, as it encompasses a wide array of medications tailored to manage symptoms associated with disorders such as depression, anxiety, and schizophrenia, making it a significant driver of both market growth and patient outcomes. Shock Treatment often serves as a vital intervention for severe cases, particularly in treatment-resistant depression, making it an important option within the market. Furthermore, the Others segment includes emerging therapies and alternative treatments such as cognitive-behavioral therapy (CBT) and mindfulness, which are gaining traction due to rising patient demand for holistic approaches. The integration of advanced technologies, such as digital therapeutics, is also influencing treatment strategies in these applications. Overall, the emphasis on personalized treatment approaches is shaping the landscape of the US Neuropsychiatric Disorders Treatment Market, addressing the diverse needs of patients while contributing to ongoing innovation in the industry. ### **Neuropsychiatric Disorders Treatment Market End User Insights** The US Neuropsychiatric Disorders Treatment Market, particularly within the End User segment, reveals a structured landscape comprising various key settings, notably hospitals, clinics, research centers, and others. Hospitals play a crucial role, serving as primary facilities for acute care and specialized treatments, leading to a significant proportion of market engagement. Clinics, often more accessible, offer ongoing care and management for chronic neuropsychiatric conditions, which fosters continuity of treatment for patients. Research centers contribute significantly to advancements in understanding neuropsychiatric disorders and developing innovative therapeutic solutions, thus driving market growth through their commitment to research and clinical trials. Additionally, other platforms, such as outpatient services and rehabilitation facilities, serve important functions in patient recovery and management. The overall segmentation within the US Neuropsychiatric Disorders Treatment Market underscores a diverse range of treatment environments that cater to the unique needs of affected individuals, enhancing access and improving outcomes in mental health care. This varied approach not only supports the evolving nature of treatments but also highlights the importance of integrating multiple care settings to address the complexities associated with neuropsychiatric disorders. **US Neuropsychiatric Disorders Treatment Market Key Players and Competitive Insights** The US Neuropsychiatric Disorders Treatment Market boasts a diverse and competitive landscape characterized by rapid advancements in research and therapeutic options aimed at addressing a wide array of mental health conditions. The increasing prevalence of neuropsychiatric disorders, coupled with rising awareness and reduced stigma surrounding mental health, has driven extensive investment in drug development and innovative treatment mechanisms. In this market, various pharmaceutical companies vie for leadership through novel therapeutics, improved patient experiences, and strategic collaborations. Competitive strengths such as research capabilities, market access strategies, and regulatory compliance play pivotal roles in determining the success of organizations in this sector, leading to a dynamic and evolving competitive landscape. AstraZeneca has solidified its position as a significant player in the US Neuropsychiatric Disorders Treatment Market by leveraging its strong research and development capabilities, which have led to the introduction of innovative therapies. The company maintains a robust pipeline targeting various conditions, capitalizing on strategic alliances and partnerships that enhance its market presence. AstraZeneca benefits from its established brand recognition and a strong distribution network within the United States, facilitating effective communication and interaction with healthcare professionals and patients. The combination of AstraZeneca’s commitment to addressing unmet medical needs and capabilities in navigating regulatory landscapes contributes to its strengths in effectively competing in this specialized market. Roche has established itself as a formidable entity in the US Neuropsychiatric Disorders Treatment Market through a diverse portfolio that includes key products and services targeting neuropsychiatric conditions. The company's strong emphasis on research and development is coupled with a history of successful mergers and acquisitions, allowing it to expand its therapeutic offerings while enhancing its market presence. Roche's strengths lie in its comprehensive understanding of patient needs, its commitment to personalized medicine, and its extensive engagement with healthcare providers. By investing in both innovative treatment options and continued research into the underlying mechanisms of neuropsychiatric disorders, Roche positions itself strategically within the market, tapping into emerging opportunities while addressing existing challenges. **Key Companies in the US Neuropsychiatric Disorders Treatment Market Include** **US Neuropsychiatric Disorders Treatment Market Industry Developments** The US Neuropsychiatric Disorders Treatment Market has seen significant developments recently, particularly in relation to major pharmaceutical companies involved. Notably, AstraZeneca and Merck have reported advancements in their product pipelines, focusing on innovative therapies for depression and anxiety disorders as of October 2023. Roche has also expanded its offerings, emphasizing personalized medicine approaches to improve patient outcomes in neuropsychiatric conditions. In terms of mergers and acquisitions, Johnson & Johnson announced an acquisition of a smaller biotech company specializing in novel antipsychotic drugs in September 2023, further consolidating its presence in this sector. Meanwhile, both Otsuka Pharmaceutical and H Lundbeck have been actively engaging in collaborations to enhance their research capabilities, which are aimed at developing next-generation therapeutics. The growth in market valuation for companies like Eli Lilly and Company and AbbVie has been substantial as these firms continue to innovate and launch new treatments, positively impacting their competitive positions. In the last two years, increased awareness around mental health and broader access to treatment options have contributed to a surge in demand, influencing overall market dynamics within the US. ## **US Neuropsychiatric Disorders Treatment Market Segmentation Insights** ### **US Neuropsychiatric Disorders Treatment Market Type Outlook** ### **US Neuropsychiatric Disorders Treatment Market Application Outlook** ### **US Neuropsychiatric Disorders Treatment Market End User Outlook** ## Market Drivers ### Government Initiatives and Funding Government initiatives aimed at improving mental health care are a crucial driver for the neuropsychiatric disorders-treatment market. In recent years, federal and state governments have increased funding for mental health programs, recognizing the importance of addressing mental health issues. For example, the Substance Abuse and Mental Health Services Administration (SAMHSA) has allocated substantial resources to enhance access to mental health services. These initiatives not only promote awareness but also facilitate the development of new treatment options. As funding continues to grow, the neuropsychiatric disorders-treatment market is likely to see an influx of innovative therapies and support systems, ultimately benefiting patients and healthcare providers alike. ### Rising Demand for Integrated Care Models The shift towards integrated care models is reshaping the neuropsychiatric disorders-treatment market. Healthcare providers are increasingly recognizing the importance of addressing both physical and mental health in a cohesive manner. This approach not only improves patient outcomes but also enhances the efficiency of care delivery. Integrated care models often involve collaboration between mental health professionals and primary care providers, ensuring that patients receive comprehensive treatment. As more healthcare systems adopt this model, the demand for neuropsychiatric treatments is expected to rise. This trend indicates a growing recognition of the interconnectedness of mental and physical health, which is likely to drive innovation and investment in the neuropsychiatric disorders-treatment market. ### Technological Innovations in Treatment Modalities Technological advancements are significantly influencing the neuropsychiatric disorders-treatment market. Innovations such as digital therapeutics, mobile health applications, and artificial intelligence are transforming how treatments are delivered and monitored. For instance, the integration of AI in diagnostic processes can enhance the accuracy of identifying neuropsychiatric conditions, leading to more tailored treatment plans. Moreover, the use of teletherapy platforms has surged, providing patients with convenient access to mental health professionals. This shift towards technology-driven solutions is expected to increase treatment adherence and improve patient outcomes, thereby driving market growth. The neuropsychiatric disorders treatment market is poised to benefit from these advancements, as they offer new avenues for effective management of mental health conditions. ### Increasing Prevalence of Neuropsychiatric Disorders The rising incidence of neuropsychiatric disorders in the US is a primary driver for the neuropsychiatric disorders-treatment market. According to the National Institute of Mental Health, approximately 1 in 5 adults experience mental illness each year, translating to over 50 million individuals. This growing patient population necessitates enhanced treatment options and resources, thereby propelling market growth. Furthermore, the increasing awareness and acceptance of mental health issues contribute to more individuals seeking treatment, which in turn stimulates demand for innovative therapies and interventions. As the stigma surrounding mental health diminishes, the neuropsychiatric disorders-treatment market is likely to expand, with a focus on developing effective solutions to address the needs of this diverse patient demographic. ### Growing Focus on Preventive Mental Health Strategies The increasing emphasis on preventive mental health strategies is emerging as a significant driver for the neuropsychiatric disorders-treatment market. Public health campaigns and educational initiatives are promoting mental wellness and early intervention, aiming to reduce the incidence of severe mental health disorders. By focusing on prevention, healthcare systems can potentially decrease the long-term costs associated with treatment. This proactive approach encourages the development of programs and therapies that target at-risk populations, thereby expanding the market. As awareness of mental health issues continues to grow, the neuropsychiatric disorders-treatment market is likely to evolve, with a greater emphasis on preventive measures and early intervention strategies. ## Future Outlook The [Neuropsychiatric Disorders Treatment Market](https://www.marketresearchfuture.com/reports/neuropsychiatric-disorders-treatment-market-1281) is projected to grow at a 9.55% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in AI-driven diagnostic tools for early detection - Expansion of personalized medicine approaches in treatment protocols By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Disorders: Degenerative Diseases (Largest) vs. Neurotic Disorders (Fastest-Growing) In the US neuropsychiatric disorders-treatment market, the prevailing segment is Degenerative Diseases, which commands a significant share due to the aging population and increasing prevalence of conditions like Alzheimer's and Parkinson's disease. Neurotic Disorders, while currently smaller, are rapidly gaining ground, fueled by rising awareness and diagnosis rates among healthcare professionals and the general public. This dynamic creates a competitive landscape among treatment providers. Degenerative Diseases: Dominant vs. Neurotic Disorders: Emerging Degenerative Diseases remain the dominant segment in the US neuropsychiatric disorders-treatment market, characterized by chronic and progressive ailments that significantly impact the quality of life. These diseases often require long-term treatment approaches and involve a variety of therapeutic strategies, including pharmacological options and supportive care. Conversely, Neurotic Disorders represent the emerging segment, marked by conditions such as anxiety and depression, which are increasingly being recognized and addressed. This segment benefits from innovative treatment modalities and heightened patient engagement, fostering substantial growth opportunities. ### By Treatment: Drug Treatment (Largest) vs. Shock Treatment (Fastest-Growing) In the treatment segment of the US neuropsychiatric disorders-treatment market, Drug Treatment dominates the landscape due to its extensive usage and established efficacy among various disorders. It holds a significant market share, driven by a wide range of therapies available for conditions such as depression, anxiety, and schizophrenia. Meanwhile, Shock Treatment, though smaller in share, is gaining traction as an effective intervention for treatment-resistant cases, appealing to a specific demographic. Growth trends indicate a rising acceptance of Shock Treatment as a viable option, especially among practitioners looking for alternative therapies for hard-to-treat disorders. Additionally, advances in technology and clinical protocols are enabling more precise and safer delivery methods, which is contributing to its rapid adoption. The overall focus on mental health awareness is also propelling both segments, but Drug Treatment remains a staple in therapeutic practices. Drug Treatment (Dominant) vs. Shock Treatment (Emerging) Drug Treatment stands as the cornerstone of therapeutic interventions in the US neuropsychiatric disorders-treatment market, characterized by a robust array of pharmaceutical options. Its dominance is attributed to the variety of medications that cater to different neuropsychiatric conditions, enhancing patient compliance and outcomes. Conversely, Shock Treatment, while traditionally viewed as an older method, is making a notable comeback as an emerging choice for severe cases, particularly in treatment-resistant depression. The evolving perceptions around its safety and efficacy, bolstered by modern technological advancements, are positioning Shock Treatment as an essential alternative, garnering interest from both healthcare providers and patients seeking effective solutions. This dynamic showcases a dual landscape where established practices and innovative treatments coexist. ### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the US neuropsychiatric disorders-treatment market, hospitals represent the largest segment, capturing a significant share of the overall market. Clinics, while smaller in market share compared to hospitals, are on a rapid growth trajectory, catering to the rising demand for outpatient services. Both segments play crucial roles in delivering neuropsychiatric care, with hospitals providing extensive resources and specialized care, whereas clinics focus on accessibility and patient engagement. Growth trends in this market are driven by several factors including an increase in the prevalence of neuropsychiatric disorders, advancements in treatment options, and a shift towards integrated care models. Hospitals are expanding their services to meet the changing needs of patients, while clinics are emerging as preferred alternatives due to their convenience and tailored approaches. The collaboration between these segments is essential in enhancing overall patient outcomes and streamlining treatment processes. Hospitals (Dominant) vs. Clinics (Emerging) Hospitals in the US neuropsychiatric disorders-treatment market are characterized by their comprehensive facilities and the availability of multidisciplinary teams equipped to handle complex cases. As the dominant segment, they offer a range of inpatient and outpatient services, ensuring that a diverse population receives necessary care. Meanwhile, clinics are considered an emerging segment, becoming increasingly popular due to their ability to provide more personalized, accessible, and continuous care. They often leverage telemedicine and community outreach programs, making mental health services more reachable. Together, these segments maintain a vital role in addressing the needs of patients suffering from neuropsychiatric disorders, with hospitals leading in specialized treatment while clinics focus on fostering long-term patient relationships. ## Competitive Benchmarking The neuropsychiatric disorders treatment market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates of mental health conditions and a growing emphasis on innovative treatment modalities. Major players such as Johnson & Johnson (US), Pfizer Inc. (US), and Eli Lilly and Company (US) are strategically positioned to leverage their extensive research and development capabilities. These companies focus on innovation, with a particular emphasis on developing novel therapeutics and expanding their product portfolios through strategic partnerships and acquisitions. This collective approach not only enhances their competitive edge but also fosters a collaborative environment that encourages advancements in treatment options.Key business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several key players exerting significant influence. This fragmentation allows for a diverse range of treatment options, catering to various patient needs while also intensifying competition among established and emerging firms. In October Johnson & Johnson (US) announced a strategic partnership with a leading digital health company to integrate AI-driven solutions into their treatment protocols for neuropsychiatric disorders. This collaboration aims to enhance patient engagement and improve treatment outcomes through personalized care. The strategic importance of this move lies in the growing trend towards digital health solutions, which are increasingly recognized as vital components in the management of mental health conditions. In September Pfizer Inc. (US) launched a new clinical trial for a groundbreaking treatment targeting treatment-resistant depression. This initiative underscores Pfizer's commitment to addressing unmet medical needs within the neuropsychiatric space. The significance of this trial is profound, as it not only positions Pfizer as a leader in innovative treatment approaches but also reflects the company's proactive stance in responding to the evolving landscape of mental health care. In August Eli Lilly and Company (US) expanded its portfolio by acquiring a biotech firm specializing in neuropsychiatric therapies. This acquisition is indicative of Eli Lilly's strategy to bolster its research capabilities and diversify its offerings. The strategic importance of this acquisition lies in its potential to accelerate the development of new therapies, thereby enhancing Eli Lilly's competitive positioning in a rapidly evolving market. As of November current competitive trends in the neuropsychiatric disorders-treatment market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and collaboration. Looking ahead, competitive differentiation is likely to evolve, with a pronounced shift from price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This transition suggests that companies that prioritize these elements will be better positioned to thrive in the future. ## Recent News & Developments The US Neuropsychiatric Disorders Treatment Market has seen significant developments recently, particularly in relation to major pharmaceutical companies involved. Notably, AstraZeneca and Merck have reported advancements in their product pipelines, focusing on innovative therapies for depression and anxiety disorders as of October 2023. Roche has also expanded its offerings, emphasizing personalized medicine approaches to improve patient outcomes in neuropsychiatric conditions. In terms of mergers and acquisitions, Johnson & Johnson announced an acquisition of a smaller biotech company specializing in novel antipsychotic drugs in September 2023, further consolidating its presence in this sector. Meanwhile, both Otsuka Pharmaceutical and H Lundbeck have been actively engaging in collaborations to enhance their research capabilities, which are aimed at developing next-generation therapeutics. The growth in market valuation for companies like Eli Lilly and Company and AbbVie has been substantial as these firms continue to innovate and launch new treatments, positively impacting their competitive positions. In the last two years, increased awareness around mental health and broader access to treatment options have contributed to a surge in demand, influencing overall market dynamics within the US. ## Report Scope | MARKET SIZE 2024 | 32.99(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 36.14(USD Billion) | | MARKET SIZE 2035 | 90.0(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.55% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Johnson & Johnson (US), Pfizer Inc. (US), Eli Lilly and Company (US), AstraZeneca PLC (GB), Bristol-Myers Squibb Company (US), Novartis AG (CH), Roche Holding AG (CH), Sanofi S.A. (FR), AbbVie Inc. (US) | | Segments Covered | Disorders, Treatment, End User | | Key Market Opportunities | Integration of digital therapeutics and personalized medicine in neuropsychiatric disorders-treatment market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the neuropsychiatric disorders-treatment market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US neuropsychiatric disorders-treatment market as of 2024?** A: The market was valued at 32.99 USD Billion in 2024. **Q: What is the projected market valuation for the US neuropsychiatric disorders-treatment market by 2035?** A: The market is projected to reach 90.0 USD Billion by 2035. **Q: What is the expected CAGR for the US neuropsychiatric disorders-treatment market during the forecast period 2025 - 2035?** A: The expected CAGR is 9.55% during the forecast period 2025 - 2035. **Q: Which segments are included in the US neuropsychiatric disorders-treatment market?** A: The segments include Degenerative Diseases, Neurotic Disorders, Psychosis, and Others. **Q: What was the market size for Drug Treatment in the US neuropsychiatric disorders-treatment market in 2024?** A: The market size for Drug Treatment was 25.0 USD Billion in 2024. **Q: How much is the market for Neurotic Disorders expected to grow by 2035?** A: The market for Neurotic Disorders is expected to grow from 10.0 USD Billion in 2024 to 25.0 USD Billion by 2035. **Q: What are the key players in the US neuropsychiatric disorders-treatment market?** A: Key players include Johnson & Johnson, Pfizer Inc., Eli Lilly and Company, and others. **Q: What was the market size for Psychosis treatment in 2024?** A: The market size for Psychosis treatment was 7.0 USD Billion in 2024. **Q: What is the expected market size for Shock Treatment by 2035?** A: The market size for Shock Treatment is expected to reach 8.0 USD Billion by 2035. **Q: What is the projected market size for Hospitals as an end user in the US neuropsychiatric disorders-treatment market?** A: The projected market size for Hospitals is expected to grow from 12.99 USD Billion in 2024 to 35.0 USD Billion by 2035. **Q: What is the projected market size of the US Neuropsychiatric Disorders Treatment Market in 2024?** A: The US Neuropsychiatric Disorders Treatment Market is expected to be valued at 30.5 USD billion in 2024. **Q: What will be the estimated market size by 2035?** A: By 2035, the market is anticipated to reach a value of 88.7 USD billion. **Q: What is the expected compound annual growth rate (CAGR) for the market during the forecast period?** A: The expected CAGR for the US Neuropsychiatric Disorders Treatment Market from 2025 to 2035 is 10.191%. **Q: Which segment dominates the market in terms of revenue in 2024?** A: In 2024, Neurotic Disorders is the dominant segment valued at 10.2 USD billion. **Q: What is the market size for Psychosis treatments in 2024?** A: The market size for Psychosis treatments is projected to be 6.3 USD billion in 2024. **Q: Which are the major players in the US Neuropsychiatric Disorders Treatment Market?** A: Key players in the market include Novartis AG, Teva Pharmaceutical Industries Ltd., and Pfizer Inc. **Q: What is the expected market value for Degenerative Diseases treatments by 2035?** A: The market value for Degenerative Diseases treatments is expected to grow to 26.1 USD billion by 2035. **Q: How much is the Others segment valued at in 2035?** A: The Others segment is anticipated to be valued at 13.0 USD billion in 2035. **Q: What is the revenue expectation for Neurotic Disorders by 2035?** A: The revenue for Neurotic Disorders is expected to reach 30.8 USD billion by 2035. **Q: What drives the growth of the US Neuropsychiatric Disorders Treatment Market?** A: Key growth drivers include increasing prevalence of neuropsychiatric disorders and advancements in treatment platforms. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-neuropsychiatric-disorders-treatment-market-19988*